Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2023 Jan 28;66(3):2205–2207. doi: 10.1021/acs.jmedchem.3c00076

Correction to “Designing Selective Drug-like Molecular Glues for the Glucocorticoid Receptor/14-3-3 Protein–Protein Interaction”

Jakob S Pallesen, Claire C Munier, Francesco Bosica, Sebastian A Andrei, Karl Edman, Anders Gunnarsson, Giuseppina La Sala, Okky Dwichandra Putra, Sonja Srdanović, Andrew J Wilson, Lisa Wissler, Christian Ottmann, Matthew W D Perry, Gavin O’Mahony
PMCID: PMC9923739  PMID: 36708352

Page 16819. Table 1 was not incorporated in its entirety in the final version. Compounds 22, 23, 24, 26, 28, (+)-28, (−)-28, and 30 (on a second page) were missing. The full table as originally submitted is as follows:

Table 1. 14-3-3ζ/GR and 14-3-3ζ/ERα PPI Stabilization by Compounds 1, 17–30.

graphic file with name jm3c00076_0001.jpg

graphic file with name jm3c00076_0002.jpg

graphic file with name jm3c00076_0003.jpg

a

TE is the stabilization effect of a compound at 200 μM and is the ratio of the signal obtained in the FP assays in the presence of the compound versus that obtained in the presence of DMSO.

b

EC1.2 is the concentration of compound (in μM) that causes a 20% increase in assay signal of the 14-3-3–phosphopeptide complex. NS: No stabilization at the tested concentrations. Measurements were performed in triplicate, and the errors represent the standard deviation of the three independent experiments.


Articles from Journal of Medicinal Chemistry are provided here courtesy of American Chemical Society

RESOURCES